Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 11/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 9/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568293 | 0.86 | CA2 (0.59) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL967958 | 0.83 | CA2 (0.50) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8599906 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL10645332 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL29445402 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL2108392 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL407503 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935402 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935393 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1567156 | 0.81 | CA2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200384111-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3725331-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-10-21 | — | — | EP | disclosed |
| CN-111727061-A | Modified carbon nanomaterial, nanocluster, substance delivery carrier and pharmaceutical composition | 国立研究开发法人产业技术总合研究所 | 2020-09-29 | — | — | CN | disclosed |
| EP-2308960-B1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | UNIV KYOTO (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-2460814-A1 | PEPTIDIC COMPOUND AND USE OF SAME | Keio University (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122797-A1 | PEPTIDIC COMPOUND AND USE OF SAME | KEIO UNIVERSITY (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | KYOTO UNIVERSITY (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2308960-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | Kyoto University (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122797-A1 | PEPTIDIC COMPOUND AND USE OF SAME | ASNS, ANPEP, NGLY1 | CA2 1748/4885HTR1A 4288/4885SIGMAR1 2400/4885 |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | EPCAM, HDGF, DSC1 | CA2 2238/4885HTR1A 2202/4885SIGMAR1 2443/4885 |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | CA2 221/4885HTR1A 822/4885SIGMAR1 522/4885 |
| US-20200384111-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | CHRM1, SLC67A1, NPSR1 | CA2 61/4885HTR1A 218/4885SIGMAR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.